1128 related articles for article (PubMed ID: 26969300)
1. Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Ren C; Ren T; Yang K; Wang S; Bao X; Zhang F; Guo W
J Exp Clin Cancer Res; 2016 Mar; 35():44. PubMed ID: 26969300
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
3. Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas.
Zhang J; Hu S; Schofield DE; Sorensen PH; Triche TJ
Cancer Res; 2004 Sep; 64(17):6026-34. PubMed ID: 15342383
[TBL] [Abstract][Full Text] [Related]
4. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
5. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G
Zöllner SK; Selvanathan SP; Graham GT; Commins RMT; Hong SH; Moseley E; Parks S; Haladyna JN; Erkizan HV; Dirksen U; Hogarty MD; Üren A; Toretsky JA
Sci Signal; 2017 Oct; 10(499):. PubMed ID: 28974650
[TBL] [Abstract][Full Text] [Related]
7. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
9. Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.
Jully B; Vijayalakshmi R; Gopal G; Sabitha K; Rajkumar T
BMC Cancer; 2012 Nov; 12():513. PubMed ID: 23145994
[TBL] [Abstract][Full Text] [Related]
10. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
[TBL] [Abstract][Full Text] [Related]
11. Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).
Subbiah V; Brown RE; Jiang Y; Buryanek J; Hayes-Jordan A; Kurzrock R; Anderson PM
PLoS One; 2013; 8(7):e68985. PubMed ID: 23922674
[TBL] [Abstract][Full Text] [Related]
12. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.
Rao DD; Jay C; Wang Z; Luo X; Kumar P; Eysenbach H; Ghisoli M; Senzer N; Nemunaitis J
Mol Ther; 2016 Aug; 24(8):1412-22. PubMed ID: 27166877
[TBL] [Abstract][Full Text] [Related]
14. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
[TBL] [Abstract][Full Text] [Related]
15. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
[TBL] [Abstract][Full Text] [Related]
16. EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells.
Hu HM; Zielinska-Kwiatkowska A; Munro K; Wilcox J; Wu DY; Yang L; Chansky HA
J Orthop Res; 2008 Jun; 26(6):886-93. PubMed ID: 18271016
[TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
18. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
19. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
20. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
